General Wayne Eyre to Strengthen Focus Graphite's Engagement with Defence and Allied Partners Across Critical Supply ChainsOttawa, Ontario--(ACN Newswire via SeaPRwire.com - April 16, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the appointment of General (Retired) Wayne Eyre, former Chief of the Defence Staff ("CDS") of the Canadian Armed Forces ("CAF"), to its Advisory Board.This appointment comes at a time when global security priorities are increasingly shaped by access to secure, reliable supply chains for critical minerals essential to defence systems, energy storage, and advanced technologies.General Eyre served more than forty (40) years in the CAF, culminating as CDS from 2021 to 2024, where he led Canada's military through a period of rapidly evolving geopolitical and security challenges. Throughout his career, he commanded at all levels, including the Canadian Army and Military Personnel Command. He served on numerous overseas missions including in the Former Yugoslavia, Afghanistan, and as Deputy Commander of United Nations Command in Korea, where he was the most senior Canadian officer ever permanently stationed in the Asia Pacific region.He brings extensive operational and institutional experience across U.S. and allied defence systems, including completion of the U.S. Army Special Forces Qualification Course, the U.S. Marine Corps Command and Staff College, the U.S. Marine Corps School of Advanced Warfighting, and the U.S. Army War College. General Eyre holds a Bachelor of Science and three master's degrees in Military Studies, Operational Studies, and Strategic Studies.His decorations include the Commander of the Order of Military Merit, the Meritorious Service Cross, and multiple international honours from allied nations, recognizing his leadership and service across the globe. He is currently a Visiting Professor and Senior Fellow at the University of Ottawa's Graduate School of Public and International Affairs, and continues to advise on global security, defence transformation, and strategic leadership.In his role with Focus, General Eyre will provide strategic guidance on defence-related applications of graphite, support engagement with allied and NATO-aligned partners, and advise on positioning the Company within evolving North American and allied critical minerals frameworks."Our high-quality material and thermal purification process lends itself to defence and advanced systems," said Dean Hanisch, CEO of Focus Graphite. "General Eyre's leadership at the highest levels of the Canadian Armed Forces, combined with his deep experience across NATO and allied operations, brings critical insight to our strategy. His perspective will help position Focus Graphite as a trusted supplier supporting defence, energy, and advanced material systems across allied nations.""The character of modern security is changing, with supply chains becoming as critical as the systems they support," said General Wayne Eyre. "Materials like graphite are foundational to energy storage, advanced technologies, and defence readiness. Focus Graphite is well positioned to contribute to strengthening secure, sovereign supply chains, and I look forward to supporting the Company as it advances its role within Canada and across NATO partners."This appointment further strengthens Focus Graphite's positioning at the intersection of critical minerals, defence readiness, and advanced materials development. The Company continues to advance its Lac Knife and Lac Tetepisca projects, alongside downstream processing initiatives, to support a secure and resilient North American supply chain.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures an eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comLinkedIn: https://www.linkedin.com/company/focus-graphite/X: https://x.com/focusgraphiteInvestors Contact:Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the anticipated contributions of General Wayne Eyre in his role as an advisor to the Company; the Company's ability to leverage his experience to support engagement with defence stakeholders, NATO-aligned partners, and allied supply chain initiatives; the growing importance of secure, North American sources of graphite for defence, energy storage, and advanced technologies; and the Company's plans and objectives for advancing its Lac Knife and Lac Tétépisca projects, downstream processing capabilities, and broader critical minerals strategy.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/292837 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 16, 2026 - (ACN Newswire via SeaPRwire.com) - Sigenergy Technology Co., Ltd. (“Sigenergy” or “the company” Stock Code: 06656.HK) officially commenced trading on the Main Board of the Hong Kong Stock Exchange (HKEX) today. As the first “AI + All-in-One PV Storage” company to list on the exchange, Sigenergy has set a new record for the fastest IPO by a Chinese enterprise.The stock showed strong momentum on its debut, opening at HK$ 581, representing almost an 80% increase over the offer price. Market cap exceeded HK$140 billion. Based on the offer price of HK$324.20 per share, the company raised over HK$4.4 billion in its IPO. If the over-allotment option (greenshoe) is exercised in full, the total proceeds will reach HK$5.06 billion.A Milestone for the Company, the Beginning for a New ChapterFounded only 3 years and 11 months ago, Sigenergy’s rapid path to listing reflects its focus on defining new industry standards rather than following short-term market trends. The IPO attracted a prestigious group of cornerstone investors, highlighting the company’s strategic value in the 2026 Hong Kong market.At the listing ceremony, Mr. Xu Yingtong, Founder and CEO of Sigenergy, together with Mr. Zhang Xianmiao, President of Sigenergy, witnessed this pivotal milestone in the company’s journey.Mr. Xu Yingtong stated: “Listing marks a new beginning for us. Guided by our ‘AI in All’ mission, we are doubling down on energy storage and accelerating R&D to fortify our competitive edge. Our goal is to ensure that AI translates into tangible value for our customers. As we advance our global expansion and refine our international network, we are proud to share the story of ‘China’s Intelligent Manufacturing’ in the renewable energy sector. We promise to uphold the highest standards of operational excellence, rewarding your trust with exceptional results and building a legacy as a transparent, reliable, and socially responsible enterprise.” Sigenergy’s cornerstone investors include world-class sovereign wealth funds and asset managers such as Temasek, Goldman Sachs Asset Management, UBS Asset Management, and BNP Paribas Asset Management. Other notable participants include Hillhouse, CPE, Boyu Capital, Gaoyi Asset Management, and Greenwoods Asset Management, alongside insurance and specialized funds like CPIC, ORIX, and Walden International.This diverse group of high-caliber investors signals a strong market consensus: Sigenergy is recognized as a unique player in the “AI + All-in-One PV Storage” sector, underpinned by proprietary technology, high entry barriers, and predictable growth. Beyond a mere endorsement of the company, this capital influx confirms the market’s conviction that “AI-native” architecture is the definitive standard for next-generation energy storage.Market confidence is supported by Sigenergy’s rapid scale-up. According to the prospectus, the company’s revenue grew from RMB 58.30 million in 2023 to RMB 9.00 billion in 2025, increased 154.4 times in two years. During this period, gross margins expanded from 31.3% to 50.1%, with an adjusted net margin reaching 35.9%. These figures validate the commercial viability of Sigenergy’s “AI-native” technology path.Differentiation Through “AI-Native” TechnologyUnlike traditional “hardware-first, AI-enabled” peers, the company established a more thorough “AI-native” path by integrating artificial intelligence across product design, manufacturing, and business models, the company has achieved a system that is inherently intelligent and capable of continuous evolution.Its flagship product, SigenStor, is a five-in-one system that combines an inverter, EV DC charging module, and battery pack into a modular, stackable unit which achieves a deep integration of power electronics, cloud and AI technologies, enhances product performance while delivering a more convenient user experience.The actual value of system’s “AI-native” capabilities is particularly effective in markets with dynamic electricity pricing. Facing fluctuations on an hourly or even minute-by-minute basis, traditional “charge at low, use at high” strategies based on fixed rules are no longer sufficient. By analyzing real-time prices, weather forecasts, and consumer habits, the system optimizes energy scheduling. In the Swedish market, SigenStor helped users reduce electricity costs by an average of 70.3%, showing the effective translation from AI technology into tangible financial benefits.Sigenergy continuously strengthens its competitive edge through a “Data-Intelligence” closed-loop. As global install base grows, the system leverages real-world operational data to undergo autonomous learning and optimization. This evolution directly translates into superior economic returns for users, which in turn fosters brand loyalty and higher retention. This data-driven cycle creates a powerful network effect, establishing a formidable, long-term barrier to entry in the Energy AI sector.Since its launch, SigenStor has established a strong global presence through its unique value proposition. According to Frost & Sullivan, Sigenergy has become the world No.1 provider of stackable distributed PV and storage all-in-one solutions in 2024, securing a 28.6% market share. Further data from SunWiz confirms that in 2025, the company ranked first in the under-1000kWh segment across Australia, Ireland, and South Africa, while maintaining a top-tier position in the UK, Sweden, and the Netherlands. This deep penetration into high-value markets has delivered significant commercial returns and reinforced Sigenergy’s brand equity. As the company expands into the Asia-Pacific and Latin American regions, its growth trajectory remains robust.To support the trajectory, the company has built a robust manufacturing footprint with production bases in Lingang and Jinqiao, Shanghai, as well as Nantong, Jiangsu. By the end of 2025, the company achieved an annual design capacity of nearly 360,000 inverters and over 5.6 GWh of energy storage batteries. This infrastructure provides a stable foundation for the company’s ongoing global expansion.The successful HKEX listing marks a significant milestone in Sigenergy’s commitment to innovation and recognizes its substantial growth potential. Entering this new chapter, and with the support of premier institutional investors, Sigenergy will focus on optimizing resource integration and accelerating its global ‘AI + Energy Storage’ strategy. By solidifying its technological leadership and market presence, the company aims to build a sustainable foundation for long-term value creation.For inquiries, please contact:EVER BLOOM (HK) COMMUNICATIONS CONSULTANTS GROUP LIMITEDMs. Claire ZhangTel: (852)3468 8171Email: project_alps.list@everbloom.com.cn Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

台北, 2026年4月16日 - (亚太商讯 via SeaPRwire.com) - OBI Pharma, Inc.（TPEx:4174.TWO）今日宣布将出席 AACR 2026 年会，并通过十篇海报展示其 GlycOBI® 平台的变革性潜力。传统 ADC 常因随机偶联而受到限制，导致药物与抗体比值（DAR）不均一、稳定性不足以及治疗窗口狭窄。相比之下，OBI 的位点特异性糖链技术可实现高度均一的 DAR，从而带来更优的 PK/PD 特征，并降低脱靶毒性，这一点已在 OBI 的主要项目 OBI-902 和 OBI-904 中得到验证。我们正通过新一代双特异性（OBI-201）以及双特异性双载荷（OBI-221）ADC 推动精准肿瘤学的进一步发展。这些“以生物学驱动”的分子旨在克服肿瘤异质性和多药耐药性——这是当前癌症治疗中的关键挑战。通过结合 GlycOBI® 与 GlycOBI DUO® 平台，OBI 正在开发具有创新性和差异化的疗法，以满足难治性实体瘤患者尚未被满足的医疗需求。此外，OBI 强大的 ADC 偶联平台已被证明能够稳定实现产品质量与可扩展性，同时支持向下一代治疗模式拓展，包括降解剂-抗体偶联物（DAC）。这些数据将于 2026 年 4 月 17 日至 22 日在美国加利福尼亚州圣地亚哥举行的美国癌症研究协会（AACR）年会上展示。“在 OBI，我们致力于打造更优质的 ADC，”OBI Pharma 首席科学官陈雅琪博士表示。“我们的目标是提供不仅能够更有效、更精准靶向肿瘤，同时还能减少副作用的疗法，为患者带来具有潜在改变生命意义的治疗选择。”2026年4月20日（星期一）（上午9:00 - 12:00）标题：通过 OBI-902 克服耐药性：下一代 TROP2 ADC 的临床前评估1 作者：Ren-Yu Hsu, Chi-Huan Lu, Chi-Sheng Shia, Jing-Rong Huang, Hsin-Shan Wu, Lu-Tzu Chen, Jhih-Jie Yang, Tzu-Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Ya-Chi Chen。OBI Pharma, Inc，台湾台北 会议主题：PO. ET07.01 - 定量药理学与转化建模 地点：海报区 17 海报编号：6 摘要编号：1818标题：OBI-904，一种靶向 Nectin-4 的下一代 Exatecan ADC，展现出增强的细胞毒性并克服 Enfortumab Vedotin 耐药性2作者：Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Shin-Jin Lin, Ting-Yu Chang, Hong-Syuan Lin, Wei-Jhen Huang, Ya-Chi Chen。OBI Pharma, Inc，台湾台北会议主题：PO.ET02.02 - 抗体药物偶联物与连接子工程 2 地点：海报区 13 海报编号：26 摘要编号：1729标题：OBI-904，一种基于糖链的位点特异性靶向 Nectin-4 的 ADC，在非临床研究中展现出强效且持久的抗肿瘤活性，并具有改进的 PK 特征及克服 EV 耐药性的能力3 作者：Chi-Huan Lu, Ren-Yu Hsu, Jing-Jie Ciou, Tzu Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Jing-Rong Huang, Ya-Chi Chen。OBI Pharma, Inc., 台湾台北会议主题：PO.ET07.01 - 定量药理学与转化建模 地点：海报区 17 海报编号：7 摘要编号：1819标题：具有双载荷的 MET/HER3 抗体药物偶联物：一种消除肿瘤逃逸机制的双靶点策略5 作者：Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Ting-Yu Chang, Hong-Syuan Lin, Cheng-Yen Wei, Shin-Jin Lin, Lu-Tzu Lu, Meng-Hsin Liu, Wei-Jhen Huang, Ya-Chi Chen。OBI Pharma, Inc., 台湾台北会议主题： PO.CL.0705 - 靶向抗原疗法与免疫 地点：海报区 49 海报编号：17 摘要编号：2665标题：引导-效应 bsADC：通过协同内吞作用提升载荷递送效率6作者：Wei-Jhen Huang, Woan Eng Chan, Meng-Hsin Liu, Yueh Chin Wu, Ya-Chi Chen。OBI Pharma, Inc., 台湾台北会议主题： PO.ET02.02 - 抗体药物偶联物与连接子工程 2 地点：海报区 13 海报编号：27 摘要编号：1730标题：亲水性增强的连接子技术实现位点特异性的降解剂-抗体偶联物，具有改进的稳定性和增强的活性7 作者：Yu-Hung Chen, Wei-Chien Tang, Chi-Dian Lu, Hung-Yi Lin, Wei-Jhen Huang, Nan-Hsuan Wang, Ya-Chi Chen, Teng-Yi Huang。OBI Pharma, Inc., 台湾台北会议主题：PO.ET02.02 - 抗体药物偶联物与连接子工程 2 地点：海报区 13 海报编号：28 摘要编号：1731标题：基于细胞的载荷释放揭示双载荷 ADC 中设计、位点及细胞依赖的比例变化8 作者：Nan-Hsuan Wang, Wei-Han Lee, Evelyn He, Li Chuan Huang, Yu-Chao Huang, David Teng-Yi Huang, Ya-Chi Chen。OBI Pharma, Inc., 台湾台北会议主题： PO.CH01.06 - 抗体、抗体药物偶联物与核酸 地点：海报区 38 海报编号：5 摘要编号：23972026 年 4 月 20 日（星期一）（下午 2:00 - 5:00）标题：TROP2 上调及其与 HER2 的相互作用介导曲妥珠单抗耐药性4 作者：Yuan-Liang Wang, Chi-Huan Lu, Cheng-Yen Wei, Jye-Yu Huang, Woan-Eng Chan, Lu-Tzu Chen, Ya-Chi Chen。OBI Pharma, Inc., 台湾台北会议主题：PO.ET03.06 - 药物耐药性 1：抗体与 ADC 地点：海报区 12 海报编号：18 摘要编号：29722026 年 4 月 21 日（星期二）（上午 9:00 - 12:00）标题：基于糖链的位点特异性 ADC 通过改进的载荷递送和免疫激活实现持续的肿瘤控制9 作者：Liu Chih-Chun, Tsai Yi-Chien, Huang Jing-Rong, Lo Fei-Yun, Pei Yu, Hsu Ren-Yu, Tu Tzu-Hsuan, Chen Ya-Chi。OBI Pharma, Inc., 台湾台北会议主题： PO.IM02.04 - 癌症中的适应性免疫 地点：海报区 6 海报编号：2 摘要编号：4234标题：通过新一代位点特异性糖链偶联与双载荷灵活性推进 ADC 治疗的发展10 作者：Wei-Chien Tang, Yu-Hung Chen, Chih-Kang Chang, Ting-Wei Liu, Hung-Yi Lin, Wei-Jhen Huang, Chi-Huan Lu, Ren-Yu Hsu, Nan-Hsuan Wang, Ya-Chi Chen, Teng-Yi Huang。OBI Pharma, Inc., 台湾台北会议主题： PO.ET02.03 - 抗体药物偶联物与连接子工程 3 地点：海报区 12 海报编号：1 摘要编号：4423电子海报将于 4 月 17 日太平洋时间中午 12:00 起在 AACR 虚拟会议平台上线供浏览，同时也将于 4 月 18 日起在 OBI Pharma 官网（www.obipharma.com）上线。1 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/45832 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/53853 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/45884 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/50305 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/40516 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/54007 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/54018 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/64749 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/131110 AACR 2026 年年会摘要在线发布 https://www.abstractsonline.com/pp8/#!/21436/presentation/5403关于 OBI PharmaOBI Pharma 是一家处于临床阶段的全球肿瘤学公司，成立于 2002 年，总部位于台湾。公司与其子公司 OBI Pharma USA, Inc. 致力于开发创新癌症疗法，为具有紧迫医疗需求的患者提供新的治疗选择。OBI 的研究重点是新型抗体药物偶联物（ADC）。通过其专有的下一代偶联技术平台 Obrion™，OBI 建立了多样化的 ADC 设计模式。该平台整合了专有的偶联和连接子技术，包括 GlycOBI®、GlycOBI DUO®、EndoSymeOBI®、HYPrOBI®，以及新型不可逆半胱氨酸偶联技术 ThiOBI®，以推进下一代 ADC 解决方案。OBI 已开发出一系列下一代 ADC 项目，包括单特异性 ADC，如处于 I 期临床评估阶段的 OBI-902（TROP2）和 OBI-904（Nectin-4）；双特异性单载荷 ADC OBI-201（HER2 × TROP2）；以及双特异性双载荷 ADC OBI-221（cMET × HER3）。为拓展 HYPrOBI® 连接子技术的应用范围，OBI 进一步开发了 ThiOBI® 技术，以实现不可逆的基于半胱氨酸的偶联。除 ADC 项目外，OBI 的资产还包括 OBI-3424，这是一种同类首创的小分子前药，靶向 AKR1C3，可在醛酮还原酶 1C3 高表达的肿瘤中选择性释放强效 DNA 烷化剂。更多信息请访问 www.obipharma.com 。关于 OBI-902 和 OBI-992OBI-902 是一种靶向 TROP2 的抗体药物偶联物（ADC），携带强效拓扑异构酶 I 抑制剂载荷，以药物-抗体比值（DAR）为 4 杀伤肿瘤细胞。TROP2 在多种实体瘤中高度表达，如乳腺癌、肺癌、胆道癌、胆管癌（胆管细胞癌）、卵巢癌、胃癌等多种癌症类型，因此成为理想的癌症治疗靶点。OBI-902 是一种新型位点特异性糖链偶联 ADC，采用 OBI 专有的 GlycOBI® 平台，具有更高的稳定性和更强的亲水性。在多种肿瘤模型中（包括非小细胞肺癌、三阴性乳腺癌和胃癌），OBI-902 展现出显著的抗肿瘤疗效、改进的药代动力学特征以及良好的安全性。其 IND 已于 2025 年 4 月 30 日获得美国食品药品监督管理局（US FDA）批准，并分别于 2025 年 11 月 16 日和 12 月 5 日获得胆管癌及胃癌（包括胃食管结合部癌）的孤儿药资格认定。I/II 期临床试验（NCT07124117）正在进行中，I 期 a 部分预计于 2027 年上半年完成。OBI-992 是另一种靶向 TROP2 的抗体药物偶联物（ADC），通过基于半胱氨酸偶联的亲水性可酶切连接子，以药物-抗体比值（DAR）为 4 携带强效拓扑异构酶 I 抑制剂载荷。OBI-992 在体循环中保持稳定，并将该细胞毒性载荷递送至表达 TROP2 的肿瘤细胞，从而在避免脱靶毒性的同时实现肿瘤细胞杀伤。OBI-992 的 IND 申请已于 2024 年 1 月获得美国 FDA 批准，并于 2024 年 8 月获得用于治疗胃癌（包括 GEJC）的孤儿药资格认定。I/II 期研究（NCT06480240）已达到拟定的 II 期推荐剂量（pRP2D），I 期预计于 2027 年上半年完成。自 2021 年 12 月起，OBI 已获得 Biosion, Inc.（www.biosion.com）授予的 TROP2 靶向抗体氨基酸序列在除中国大陆、香港和澳门以外所有地区的独家许可。Biosion 在中国大陆、香港和澳门拥有该抗体序列的独家权利。OBI 在除中国大陆、香港和澳门以外的所有地区拥有 OBI-992 和 OBI-902 的商业权利，而 Biosion 在中国大陆、香港和澳门拥有相应的商业权利。关于 OBI-904OBI-904 是一种抗体药物偶联物（ADC），由特异性靶向 Nectin-4（Nectin 细胞黏附分子 4）的单克隆抗体构成，通过 OBI 专有的 GlycOBI® ADC 赋能技术，并在双功能酶 EndoSymeOBI® 和新型连接子 HYPrOBI® 的支持下，以药物-抗体比值（DAR）为 8 偶联强效拓扑异构酶 I 抑制剂载荷。该药物有望成为同类首创及同类最佳的基于糖链的 ADC，旨在靶向多种表达 Nectin-4 的癌症类型。在多种动物疾病模型中（包括头颈鳞癌、结直肠癌、三阴性乳腺癌、宫颈癌及肉瘤），其已显示出抗肿瘤活性；在猴重复给药毒性研究中，OBI-904 展现出良好的安全性，目前处于 IND 申请前开发阶段。关于 OBI-201OBI-201 是一种 TROP2 × HER2 双特异性 ADC，基于 OBI 的 GlycOBI® ADC 赋能技术构建，并偶联拓扑异构酶 I 抑制剂。值得注意的是，OBI 首次证明 HER2 与 TROP2 可在细胞表面相互作用并形成蛋白复合物——这一突破性发现得益于与专业 AI 药物研发合作伙伴的协作。与单特异性 TROP2 或 HER2 ADC 相比，OBI-201 具有多项优势。通过同时靶向两种抗原，它可扩大肿瘤覆盖范围，尤其适用于靶点表达异质性或表达水平较低的癌症。双靶向可增强肿瘤选择性、结合亲和力及内吞作用，从而提高载荷向癌细胞的递送效率，同时有望降低对正常细胞的毒性。OBI-201 还可能克服部分单特异性 ADC 治疗后因靶点下调所产生的耐药性。动物研究表明，在 HER2 表达极低的耐药性乳腺癌模型中，OBI-201 相较于单靶点 ADC 展现出显著更优的抗肿瘤活性。OBI-201 能够持续抑制肿瘤生长，显示出其克服多种耐药机制的潜力。OBI-201 是一种新一代双特异性 ADC，有望突破单靶点 ADC 的局限，为患者提供更全面且持久的治疗选择。关于 OBI-221OBI-221 是一种双特异性双载荷 ADC（BsDpADC），基于 OBI 的 GlycOBI DUO® 技术构建，靶向 cMET 和 HER3，并偶联 MMAE 与拓扑异构酶 I 抑制剂双载荷。在临床实践中，靶向 EGFR 的疗法已成为治疗非小细胞肺癌（NSCLC）和结直肠癌（CRC）的关键策略。然而，肿瘤常通过上调 cMET 和 HER3 快速产生耐药性，从而维持肿瘤生长。此外，在胃癌、头颈癌及多种其他实体瘤中也观察到 cMET 和 HER3 的高表达，进一步凸显了未被满足的医疗需求。为应对这一挑战，OBI Pharma 利用其专有的 GlycOBI DUO® 平台和 HYPrOBI® 连接子开发了新型双特异性双载荷抗体药物偶联物（BsDpADC）——OBI-221。该治疗药物可同时靶向 cMET 和 HER3，并递送具有协同作用的细胞毒性载荷，从而有效对抗肿瘤耐药性和异质性。这一突破性设计不仅满足未被满足的医疗需求，也代表了下一代 ADC 开发的前瞻性策略。OBI-221 在克服现有 EGFR 靶向疗法耐药性方面具有重要潜力，有望为患者提供更具针对性的治疗选择，并带来显著的临床价值。关于 GlycOBI®OBI 开发了一种独特的基于糖链的位点特异性 ADC 技术（GlycOBI®），采用即插即用（Plug and Play）设计，可兼容任意抗体、连接子和载荷，并支持多种药物-抗体比值（DAR）（最高可达 16）。该技术由 OBI 专有的双功能酶技术 EndoSymeOBI® 和亲水性连接子技术 HYPrOBI® 驱动，作为 OBI Obrion™ ADC 技术体系的核心组成部分，能够在 GMP 条件下通过高效、可规模化、流程简化的两步一锅法偶联工艺生成位点特异性且高度均一的 ADC。在偶联过程中，GlycOBI® 避免破坏抗体结构，并确保生成的 ADC 保持与天然抗体相当的生物物理特性。此外，OBI 的连接子技术提高了载荷偶联效率，并降低了聚集或降解的倾向，从而进一步支持稳定且可控的 ADC 生产过程。GlycOBI® 克服了传统 ADC 方法常见的局限，并在多项体内研究中展现出更优的抗肿瘤活性和稳定性。值得注意的是，该平台支持偶联细胞毒性小分子抑制剂以及高度疏水性的降解剂，从而拓展至包括 DAC 在内的下一代治疗模式。关于 GlycOBI DUO®GlycOBI DUO® 是一种基于 GlycOBI® 位点特异性偶联平台及其专有酶促偶联策略构建的下一代双载荷抗体药物偶联物（ADC）技术。该技术可在单一抗体上以可调比例精确、可编程地连接两种不同载荷，并支持高 DAR 比值（最高可达 DAR24）。通过结合互补的作用机制，GlycOBI DUO® 旨在增强抗肿瘤疗效、应对肿瘤异质性并提升整体治疗指数，同时具备克服传统 ADC 相关耐药机制的潜力，代表了下一代 ADC 开发的重要进展。关于 ThiOBI®OBI 开发了一种新型不可逆半胱氨酸偶联 ADC 平台（ThiOBI®），具有更高的稳定性，可适用于任意抗体、连接子和载荷。OBI 专有的 ThiOBI® 平台结合连接子技术（HYPrOBI®），可生成多种生物分子形式的 ADC，包括抗体片段、纳米抗体、肽类和蛋白质。此外，OBI 的 HYPrOBI® 连接子技术提高了载荷的偶联效率，降低了聚集倾向，并延长了 ADC 产品的半衰期。ThiOBI 克服了传统半胱氨酸 ADC 的局限，并在多项体内研究中实现了更优的抗肿瘤活性和稳定性。GlycOBI®、EndoSymeOBI®、ThiOBI®、HYPrOBI® 和 GlycOBI DUO® 为 OBI 的注册商标。Obrion™ 为正在申请注册的商标。前瞻性声明本新闻稿中非历史事实的陈述属于《1995 年私人证券诉讼改革法》所定义的前瞻性声明。此类前瞻性声明包括但不限于关于未来临床试验、试验结果及其时间安排的陈述。相关风险因素已在 OBI Pharma 的报告和演示材料中不时披露，包括其向台湾证券期货局提交的文件。公司联系人:Jukka MuhonenExecutive Director, Business DevelopmentOBI Pharma USA, Inc.1.617.821.0292 jukkamuhonen@obipharma.com来源: OBI Pharma USA, Inc. Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BRISBANE, AUS, Apr 15, 2026 - (ACN Newswire via SeaPRwire.com) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to provide the latest progress update on the Graphene Aluminium-Ion Battery technology ("G+A CELLS") being developed by GMG and the University of Queensland ("UQ") under a Joint Development Agreement with Rio Tinto, one of the world's largest metals and mining groups, and with the support of the Battery Innovation Center of Indiana ("BIC") in the United States of America.The GMG G+A CELLS have now demonstrated superior performance characteristics when compared to a representative market leading ultra-fast charging batteries, the Lithium Titanate Oxide ("LTO") batteries, which can be sold at a premium price of up to US$1200/kWh.1Figure 1 shows the current energy density of G+A CELLS, based on BIC testing, and shows the doubling in performance (26 to 49 Wh/kg) since the previous announcement in December 20252 and in comparison, to a representative market leading fast charging high power LTO batteries.Figure 1: Increase in Energy Density for G+A CELLS since December '25 UpdateTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure1.jpgFigure 2 shows the charge and discharge curves for the G+A CELLS when charged in 6 minutes (10C) and 60 minutes (1C). The energy density of the cells for the G+A CELLS when charged in 60 minutes (1C) is now 101 Wh/kg when charging to 100% State of Charge (SOC) which is an increase from 58 Wh/kg from the previous update. This shows the G+A CELLS have a nominal voltage of approximately 3.2 Volts (an increase from 3.0 Volts in the previous update). The G+A CELLS maintained performance over hundreds of cycles at 6-minute fast charging rate (10C).Figure 2: Battery performance curves of G+A CELLS at 60 min and 6min charge (1C & 10C)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_001full.jpgBob Galyen, GMG Non-Executive Director and former CTO of CATL - the largest battery manufacturer in the world, commented: "With the possibility of charging from empty to full in around six minutes, this chemistry fundamentally changes how designers can think about electric vehicles, consumer electronics, and stationary storage. Instead of planning around long charge stops with large packs, engineers can optimise for rapid energy turnaround, with higher power, and safer, with GMG's battery made from abundant raw materials. Lithium-ion will remain a key part of the energy landscape for years to come, but its limitations in fast charging, temperature tolerance, and critical-mineral supply are increasingly evident. By leveraging aluminium and graphene, the GMG team is demonstrating a pathway to reduce reliance on traditional lithium-based systems and or combinatorial systems with multiple battery technologies while delivering step-change improvements in charge time and power density. This is not an incremental tweak to existing cells - it is a new platform that can open markets and use cases that were previously uneconomic or impractical. The companies that adapt quickest to this shift will lead the next wave of electrification, and GMG intends to be at the centre of that transition with graphene aluminium-ion technology."Standard commercial Lithium Nickel Manganese Cobalt ("LNMC") and Lithium Iron Phosphate ("LFP") battery cells for electric vehicles and stationary storage are NOT designed for continuous 6-minute charging (10C); typical recommended charge rates are ≤1 hour (1C), often 2 hours (0.5C), with only limited fast charge operation. Only specialized high-power cell designs like LTO battery cells can tolerate charge rates of 6 minutes (10C).3GMG has now developed a completely new hybrid electrolyte that is chloride free and non-corrosive, unlike common aluminium battery electrolytes, along with a complex cathode and anode technology that enables very stable fast charging over hundreds of cycles. The substrate for both the cathode and anode in the G+A CELLS is aluminium foil - which provides significant cost and weight savings compared with copper, the substrate material used in most lithium and sodium-ion batteries. GMG's technology does not include the use of lithium or copper. The Company has submitted an additional patent application covering these new developments.GMG believes that it has significantly met the key target specification requirements for use in heavy mobile equipment, as shown in Figure 3, its main targeted use case, including:- Charging in under 6 minutes;- Energy density > 100 Wh/kg after 1 hour of charging; and- Safe (no Lithium).The next battery development steps include the following activities:- Test and show cycle life up to 10,000 cycles- Test and show ambient temperature impacts- Test and show standard safety testing- Test and show no thermal battery management system needed Figure 3: G+A CELLS Battery Use Case - heavy mobile equipmentTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure3.jpgCraig Nicol, GMG Managing Director and CEO, commented: "This is a significant step up from where we were at with battery performance in December 2025 and we see the required performance for our targeted use case being largely met - which means we can start to put together the next stages of the battery maturation program - including partnerships and manufacturing plans."GMG management believes that the G+A CELLS can eventually achieve over 160 Wh/kg when charged in 1 hour, and over 80 Wh/kg when charged in 6 minutes with further development of the cathode, anode, electrolyte and component weights.Figure 4 shows the latest G+A CELLS in pouch format:Figure 4: Current Multi-Layer G+A CELLTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure4.jpgBattery Technology Readiness LevelThe battery technology readiness level ("BTRL") of the G+A CELLS remains at Level 4, whilst significantly progressed through this level as shown in Figure 5. GMG is currently in the process of completing the optimization of the electrochemical behaviour for the pouch cells via ongoing laboratory experimentation. Through collaboration with BIC, it is anticipated that the battery technology readiness will ultimately progress to BTRL 7 and 8 since the equipment and processes needed to produce the G+A CELLS are the same as those employed to make Lithium-Ion Batteries, though no definitive timeline for achievement can be provided at this time.Figure 5: Battery Technology Readiness Level (BTRL)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_004full.jpgThe Company is confident it can meet the overall timeline, as seen in Figure 6, of its battery cell roadmap that calls for testing of cells with customers in 2026 and small commercial production with support of various partners, including BIC, in 2027.Figure 6: Battery Cell RoadmapTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_005full.jpgNext Steps Toward Commercialisation & Market ApplicationsJack Perkowski, GMG Non-Executive Chairman and Director, commented: "I am extremely proud that GMG has progressed its battery to this stage - the Company is getting very close to final commercialisation steps. We look forward to providing further updates as GMG progresses the development of its battery technology."The Company continues to see a broad range of potential applications for a completed G+A CELLS - utilising its ultra-high power-density and economic energy density characteristics. Along with Rio Tinto, a range of global companies have confidentially expressed their interest in working with GMG in the following vertical sectors:Figure 7: Market ApplicationsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_006full.jpgCurrently, GMG believes it will use a plastic battery pack design, similar to Figure 8, to hold the battery pouch cells - reducing the weight, cost and complexity relative to using a metal case. Using a plastic battery pack is possible for two main reasons - GMG believes that its battery will not require a thermal management system or the fireproofing precautions provided by the metal case in a lithium-ion battery. Using plastic will increase the comparative energy density of G+A CELL packs when compared to lithium-ion batteries.Figure 8: Expected Battery Pack for GMG's G+A CELLS Pouch FormatTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_9a72ca9bb4963a29_007full.jpgComparison and Market Review: LTO Batteries As shown in Figure 9 below, the performance of GMG's G+A CELL technology is already very similar to representative LTO batteries.Figure 9: Comparison of GMG's G+A CELLS to Lithium Titanate Oxide (LTO) BatteryTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/292641_figure9.jpg LTO batteries are sold at a premium to LFP and LNMC batteries, which are the main chemistries used in electric vehicles and energy storage systems, and are also widely used in other electronic applications due to their high performance and long cycle life. The material and manufacturing costs for G+A CELLS are expected to be similar to, or less than, the cost to manufacture standard lithium-ion batteries, but substantially lower than the costs to produce LTO batteries.LTO batteries have energy density ranging from 50 - 80 Wh/kg.6 The LTO product is sold globally for use in many applications — with a total of US$5.67 billion sales per annum in 2025. Sales of LTO batteries are expected to grow at 16.9% per annum to an estimated US$ 12.5 billion by 2030. The major manufacturers of LTO batteries include Toshiba, Gree, Microvast and CATL.Further details on applications for the LTO battery from Mordor Intelligence7 are described below. In many of the use cases for LTO batteries, GMG believes that its G+A CELLS can be substituted at a substantially lower cost.Commercial Vehicles: Automotive, primarily buses, refuse trucks, and drayage tractors rather than passenger cars, is the largest user of LTO batteries. Fleets realize five-year total-cost-of-ownership parity once fuel savings and lower maintenance offset higher upfront prices.Fast-charging Electric Buses and Trucks: Transit authorities need battery systems that accept repeated high-power "opportunity charges" during short layovers. LTO cells replenish 80% capacity in roughly five minutes, allowing operators to shrink fleet size without sacrificing route frequency. U.S. Low-No Emission Bus grants earmark more than US$1.5 billion per year, with bid specifications that explicitly reference rapid-charge capability. Parallel subsidy programs in China reimburse up to CNY 80,000 (US$ 11,396) per new-energy bus, accelerating volume deployment in provincial capitals.Hybrid and BEV: Regenerative braking and high-C-rate acceleration favour the use of LTO batteries. Use in fast-charge EV stations is growing rapidly as ride-hailing fleets adopt swap-ready models.Stationary Storage: Utility-scale batteries now cycle multiple times per day for frequency regulation, peak shaving, and voltage support. Energy-storage-system integrators adopt LTO batteries for grid-frequency response where state-of-charge swings are shallow but frequent.Industrial Robotics: LTO batteries are used in continuous-duty forklifts that require partial charges during operator breaks.Aerospace and Defense: Unmanned aerial vehicles, missile auxiliaries, and soldier-worn power banks operating from -40 °C to +60 °C ambient.5-minute Battery-Swap Stations: Battery-as-a-service platforms require ultra-fast turnaround and high cycle life. CATL confirmed plans to install 1,000 swap stations in 2025 and 30,000-40,000 by 2030, each requiring packs that tolerate thousands of rapid exchanges without degradation.Sub-10 kWh Packs: Cordless construction tools, autonomous ground vehicles, and medical carts select LTO batteries to bypass daily pack swaps.12V starter replacement to Lead acid: GMG's G+A CELLS battery technology would be a viable 12 V starter-battery replacement for lead-acid, offering lower weight, longer cycle life, good low-temperature performance and improved cold-cranking capability, together with excellent tolerance to storage at 0% state of charge. In suitable system designs, the chemistry's stable voltage behaviour can also reduce balancing requirements and simplify battery management, helping to lower overall system cost.Lifecycle Procurement Preference: Many government procurement frameworks now weigh lifecycle reliability higher than purchase price. For example, New Mexico awarded a US$ 400 million bus electrification contract that included stringent thermal-runaway resistance metrics. Europe's Clean Industrial Deal allocates capital for storage technologies that stabilize renewables, aligning well with LTO batteries' fast-response profile.Cylindrical Cells: accounted for 37.7% of LTO battery sales in 2024 as entrenched production lines and robust steel casings satisfied heavy-duty demand. Pouch designs address aerospace weight requirements and constrained dashboards in autonomous robots.Summary of Important Milestones for GMG's G+A CELLS Development: MonthImportant Milestones in the Development of the Graphene Aluminium Ion BatteryMay 2020GMG and UQ win Australian Research Council grant for Graphene battery developmenthttps://graphenemg.com/gmg-and-uq-wins-australian-research-council-grant-for-graphene-aluminium-ion-battery-development/Apr 2021The University of Queensland and GMG kick off coin cell battery development projecthttps://graphenemg.com/gmg-the-university-of-queensland-research-uni-quest-kick-off-the-graphene-enhanced-aluminium-ion-battery-development-project/May 2021Graphene aluminium-ion battery performance data - Energy Density and Power Densityhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-performance-data/Jun 2021Graphene aluminium-ion battery performance data - Cycle Lifehttps://graphenemg.com/graphene-aluminium-ion-battery-performance-data/Jun 2021Significant potential battery customer market response to launch of batteryhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-progress-update/Jul 2021Investment decision for coin cell battery development centrehttps://graphenemg.com/gmg-battery-pilot-plant-investment/Oct 2021Construction starts for coin cell battery development centrehttps://graphenemg.com/construction-battery-pilotplant/Oct 2021Bosch Australia Manufacturing Solutions and GMG sign Letter of Intenthttps://graphenemg.com/gmg-and-bosch-sign-collaboration-arrangement-for-bosch-to-design-and-deliver-gmgs-graphene-aluminium-ion-battery-manufacturing-plant/Dec 2021Commencement coin cell battery development centrehttps://graphenemg.com/battery-pilot-plant/Dec 2021Initial coin cell batteries sent for customer feedbackhttps://graphenemg.com/graphene-aluminium-battery-customers-prototypes/Mar 2022Initial factory acceptance testing of semi-automated prototype battery cell assembly equipmenthttps://graphenemg.com/gmg-announces-initial-factory-acceptance-testing-of-semi-automated-prototype-battery-cell-assembly-equipment/Mar 2022Wood Engineering and GMG Sign a Letter of Intenthttps://graphenemg.com/gmg-and-wood-agree-collaboration-arrangement-for-wood-to-engineer-and-deliver-major-graphene-manufacturing-expansion-projects/May 2022Rio Tinto and GMG sign Letter of Intenthttps://graphenemg.com/gmg-riotinto-energysavings-battery/Jun 2022Commissioning of Pouch Cell Equipmenthttps://graphenemg.com/gmg-manufactures-first-pouch-cell/Jun 2022Bob Galyen, former chief technology officer of CATL, joins GMG technical advisory committee.https://graphenemg.com/gmg-technical-advisory-committee-leadership-team-additions-and-cfo-change/Aug 2022Investment decision for Phase 1 modular Graphene Production Planthttps://graphenemg.com/gmg-announces-phase-1-expansion-project-to-graphene-manufacturing-facility-for-energy-saving-products-and-batteries/Oct 2022Significant battery performance, cell and graphene production improvementshttps://graphenemg.com/gmgs-battery-update-significant-battery-performance-cell-and-graphene-production-improvements/Dec 2022Investment of $600k Battery Development Centrehttps://graphenemg.com/gmg-invests-au-600000-to-accelerate-battery-pouch-cell-customer-testing-development-in-2023/Feb 2023Australian Government Approval (AICIS) for production and sale of batteries.https://graphenemg.com/gmg-receives-regulatory-approval-to-enable-significant-commercial-sales/May 2023Battery Joint Development Agreement with Rio Tinto signedhttps://graphenemg.com/gmg-announces-battery-joint-development-agreement-with-rio-tinto/May 2023Battery Technology Readiness Level (BRTL) 2-3 reachedhttps://graphenemg.com/gmg-announces-battery-team-and-related-updates/May 2023Decision to switch to develop Pouch Cells (instead of Coin Cells)https://graphenemg.com/gmg-announces-battery-team-and-related-updates/Jul 2023Bob Galyen former chief technology officer of CATL joins GMG board of Directorshttps://graphenemg.com/graphene-manufacturing-group-appoints-former-chief-technology-officer-of-catl-limited-to-its-board-of-directors/Sep 2023Battery Pouch Cell Prototypes Multilayered Auto-Stacker Demonstrationhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-pouch-cell-prototypes-multilayered-auto-stacker-demonstration/Sep 2023Reaching 500 mAh capacity batteryhttps://graphenemg.com/gmg-achieves-500mah-graphene-aluminium-ion-battery-prototype-in-pouch-cell-format/Sep 2023Battery Technology Readiness Level (BRTL) 4 reachedhttps://graphenemg.com/gmg-achieves-500mah-graphene-aluminium-ion-battery-prototype-in-pouch-cell-format/Nov 2023Rio Tinto and GMG Partnership Video Launchedhttps://graphenemg.com/rio-tinto-gmg-battery-partnership-video-launch/Dec 2023Commissioning of modular Graphene Production Planthttps://graphenemg.com/graphene-manufacturing-group-commissions-modular-graphene-production-plant/Feb 20241000 mAh Capacity Reachedhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-1000-mah-capacity-reached-and-next-steps-toward-commercialisation/Mar 2024Graphene Manufacturing Group Secures AU$2 million Funding Grant from Queensland Government for Battery Pilot Planthttps://graphenemg.com/graphene-manufacturing-group-secures-au2-million-funding-grant-from-queensland-government-for-battery-pilot-plant/Aug 2024GMG's Graphene Aluminium-Ion Battery: Progress Update and Next Steps Toward Commercialisationhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-progress-update-and-next-steps-toward-commercialisation/Mar 2025GMG's Graphene Aluminium-Ion Battery: Collaboration with World Leading USA Battery Innovation Centre and Next Steps Toward Commercialisationhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-collaboration-with-world-leading-usa-battery-innovation-centre-and-next-steps-toward-commercialisation/Dec 2025GMG Unveils Graphene Aluminium-Ion Battery that Fully Charges in 6 minuteshttps://graphenemg.com/gmg-unveils-graphene-aluminium-ion-battery-that-fully-charges-in-6-minutes/ About BIC:BIC is a collaborative initiative designed to incorporate leadership from renowned universities, government agencies, and commercial enterprises. BIC is a public-private partnership and a not-for-profit organization focusing on the rapid development, testing and commercialization of safe, reliable and lightweight energy storage systems for defense and commercial customers. BIC is a unique organization that has been leading battery cell development for world leading battery companies for over 10 years and has carried out over 500 battery development projects.About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041www.graphenemg.comNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the pricing of LTO batteries, expectations for GMG G+AI batteries to achieve specification requirements for heavy mobile equipment, the lower cost to produce GMG G+AI batteries, expectations for GMG G+AI batteries in respect of charging time, stability, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system when development is completed, that the new hybrid electrolyte is chloride free and non-corrosive, that the cathode and anode technology employed enables very fast and stable charging, that GMG G+AI batteries provide significant cost and weight savings relative to copper, that G+AI batteries can achieve over 150 Wh/kg charged over 1 hour and 75 Wh/kg when charged over 6 minutes following further development of cathode, anode, electrolyte and component weights, that G+AI batteries will progress to BTRL 7 and 8, that the timeline for the battery cell roadmap is achievable, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and which offers weight, cost and complexity advantages to a metal case and increased energy density, expectations for the lack of a thermal management system or fireproofing precautions, expectations for material and manufacturing costs, expectations for sales of LTO batteries, expectations for G+AI batteries being substitutable for LTO batteries at lower cost, expectations that G+AI batteries are viable 12V starter battery replacements and the rationale therefor and the advantages of pouch design for aerospace weight requirements and constrained dashboards of autonomous robots.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, assumptions that GMG G+AI batteries can be produced at lower cost, as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries, the speed and stability of charging, that G+AI batteries will progress to BTRL 7 and 8, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and offer weight, cost and complexity advantages to a metal case and increased energy density, that the service agreement with the BIC will enable the Company to optimize its cell design and battery manufacturing equipment, and that the Company will be able to meet its overall timeline on the battery cell roadmap. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: that GMG G+AI batteries cannot be produced at lower cost, or any of the assumptions as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries can not be achieved, G+AI batteries do not offer expected speed and stability of charging, that G+AI batteries will not progress to BTRL 7 and 8, that a range of global companies in a variety of industries will not be interested in working with GMG, that the battery pack design will not be plastic and not offer weight, cost and complexity advantages to a metal case and increased energy density, that the Company will not be able to optimize the electrochemical behaviour of the pouch cell through laboratory experimentation or at all, that the Company will not be able to meet its overall timeline on the battery cell roadmap, that the service agreement with the BIC will not enable the Company to optimize its cell design and battery manufacturing equipment and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 04, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.1 https://www.ritarpower.com/industry_information/The-Price-of-50-kWh-Lithium-Ion-Batteries-A-Comprehensive-Analysis_297.html#:~:text=Lithium%20Titanate%20(LTO)%20Batteries%3A,cost%20between%20%2440%2C000%20and%20%2460%2C000.2 https://graphenemg.com/gmg-unveils-graphene-aluminium-ion-battery-that-fully-charges-in-6-minutes/3 https://findingspress.org/article/21459-impact-of-charging-rates-on-electric-vehicle-batt4 High-power type cells | SCiB™ Rechargeable battery | Toshiba5 https://www.ritarpower.com/industry_information/The-Price-of-50-kWh-Lithium-Ion-Batteries-A-Comprehensive-Analysis_297.html#:~:text=Lithium%20Titanate%20(LTO)%20Batteries%3A,cost%20between%20%2440%2C000%20and%20%2460%2C000.6 https://www.grepow.com/blog/battery-energy-density.html7 Lithium Titanate Oxide Battery Market Size, Share & 2030 Growth Trends ReportTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/292641 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TAIPEI, TW, Apr 15, 2026 - (ACN Newswire via SeaPRwire.com) - OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904.We are further advancing precision oncology through our next-generation bispecific (OBI-201) and bispecific, dual-payload (OBI-221) ADCs. These "biology - driven" molecules are designed to overcome tumor heterogeneity and multi-drug resistance-key challenges in current cancer treatment. By incorporating both the GlycOBI® and GlycOBI DUO® platforms, OBI is developing novel and differentiated therapeutics addressing the unmet medical need for patients with difficult-to-treat solid tumors. Additionally, OBI's robust ADC conjugation platform has proven to consistently deliver product quality and scalability, while enabling expansion into next-generation modalities, including degrader-antibody conjugates (DACs).These data will be presented at the American Association of Cancer Research (AACR) Annual Meeting from April 17 to 22, 2026 in San Diego, CA. (USA)."At OBI, we make better ADCs," said Dr. Ya-Chi Chen, Chief Scientific Officer OBI Pharma. "Our goal is to deliver therapies that not only target tumors more effectively and precisely, but also reduce side effects, giving patients potentially life-changing treatment options."Monday, April 20, 2026 (9:00 AM - 12:00 PM)Title: Overcoming Resistance with OBI-902: Preclinical Evaluation of a Next-Generation TROP2 ADC1Authors: Ren-Yu Hsu, Chi-Huan Lu, Chi-Sheng Shia, Jing-Rong Huang, Hsin-Shan Wu, Lu-Tzu Chen, Jhih-Jie Yang, Tzu-Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Ya-Chi Chen. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO. ET07.01 - Quantitative Pharmacology and Translational ModelingLocation: Poster Section 17Poster Board Number: 6Abstract Presentation Number: 1818Title: OBI-904, a Next-Generation Nectin-4-Targeting Exatecan ADC, Demonstrates Enhanced Cytotoxicity and Overcomes Enfortumab Vedotin Resistance2Authors :Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Shin-Jin Lin, Ting-Yu Chang, Hong-Syuan Lin, Wei-Jhen Huang, Ya-Chi Chen. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO.ET02.02 - Antibody-Drug Conjugates and Linker Engineering 2Location: Poster Section 13Poster Board Number: 26Abstract Presentation Number: 1729Title: OBI-904, a Glycan-based Site specific Nectin-4-Targeted ADC, Demonstrates Potent and Durable Antitumor Activity with an Improved PK Profile and Overcoming EV-Resistance in Non-Clinical Studies3Authors: Chi-Huan Lu, Ren-Yu Hsu, Jing-Jie Ciou, Tzu Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Jing-Rong Huang, Ya-Chi Chen. OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.ET07.01 - Quantitative Pharmacology and Translational ModelingLocation: Poster Section 17Poster Board Number: 7Abstract Presentation Number: 1819Title: The MET/HER3 Antibody-Drug Conjugate with Dual Payload: A Dual-Target Approach to Eliminate Tumor Escape Mechanisms5Authors: Yuan-Liang Wang, Chi-Huan Lu, Woan-Eng Chan, Ting-Yu Chang, Hong-Syuan Lin, Cheng-Yen Wei, Shin-Jin Lin, Lu-Tzu Lu, Meng-Hsin Liu, Wei-Jhen Huang, Ya-Chi Chen. OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.CL.0705 - Targeted Antigen Therapies and ImmunityLocation: Poster Section 49Poster Board Number: 17Abstract Presentation Number: 2665Title: Guide-effector bsADCs: Driving co-endocytosis for enhanced payload delivery6Authors: Wei-Jhen Huang, Woan Eng Chan, Meng-Hsin Liu, Yueh Chin Wu, Ya-Chi Chen .OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.ET02.02 - Antibody-Drug Conjugates and Linker Engineering 2Location: Poster Section 13Poster Board Number : 27Abstract Presentation Number: 1730Title: Hydrophilicity-Enhanced Linker Technology Enables Site-Specific Degrader-Antibody Conjugates with Improved Stability and Enhanced Activity7Authors: Yu-Hung Chen, Wei-Chien Tang, Chi-Dian Lu, Hung-Yi Lin, Wei-Jhen Huang, Nan-Hsuan Wang, Ya-Chi Chen, Teng-Yi Huang. OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.ET02.02 - Antibody-Drug Conjugates and Linker Engineering 2Location: Poster Section 13Poster Board Number: 28Abstract Presentation Number: 1731Title: Cell-based payload release highlights design, site, and cell-dependent ratio shifts in dual-payload ADCs8Authors: Nan-Hsuan Wang, Wei-Han Lee, Evelyn He, Li Chuan Huang, Yu-Chao Huang, David Teng-Yi Huang, Ya-Chi Chen. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO.CH01.06 - Antibodies, Antibody-Drug Conjugates, and Nucleic AcidsLocation: Poster Section 38Poster Board Number: 5Abstract Presentation Number: 2397Monday, April 20, 2026 (2:00 PM - 5:00 PM)Title:TROP2 Upregulation and Interaction with HER2 Mediate Trastuzumab Resistance4Authors: Yuan-Liang Wang, Chi-Huan Lu, Cheng-Yen Wei, Jye-Yu Huang, Woan-Eng Chan, Lu-Tzu Chen, Ya-Chi Chen. OBI Pharma, Inc., Taipei, TaiwanSession Title: PO.ET03.06 Drug Resistance 1: Antibodies and ADCsLocation: Poster Section 12Poster Board Number: 18Abstract Presentation Number: 2972Tuesday, April 21, 2026 (9:00 AM - 12:00 PM)Title: Glycan-based site specific ADC Achieves Sustained Tumor Control through Improved Payload Delivery and Immune Activation9Authors: Liu Chih-Chun, Tsai Yi-Chien, Huang Jing-Rong, Lo Fei-Yun, Pei Yu, Hsu Ren-Yu, Tu Tzu-Hsuan, Chen Ya-Chi. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO.IM02.04 - Adaptive Immunity in CancerLocation: Poster Section 6Poster Board Number: 2Abstract Presentation Number: 4234Title: Advancing ADC therapeutics with next-generation site-specific glycan conjugation and dual-payload flexibility10Authors: Wei-Chien Tang, Yu-Hung Chen, Chih-Kang Chang, Ting-Wei Liu, Hung-Yi Lin, Wei-Jhen Huang, Chi-Huan Lu, Ren-Yu Hsu, Nan-Hsuan Wang, Ya-Chi Chen,Teng-Yi Huang. OBI Pharma, Inc, Taipei, TaiwanSession Title: PO.ET02.03 - Antibody-Drug Conjugates and Linker Engineering 3Location: Poster Section 12Poster Board Number: 1Abstract Presentation Number: 4423The e-posters will be available for browsing at the AACR virtual meeting platform beginning at 12:00 PM PT on April 17, as well as on the OBI Pharma website (www.obipharma.com) beginning on April 18.1 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/45832 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/53853 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/45884 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/50305 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/40516 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/54007 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/54018 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/64749 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/131110 AACR Annual Meeting 2026 Abstracts online https://www.abstractsonline.com/pp8/#!/21436/presentation/5403About OBI PharmaOBI Pharma is a clinical-stage global oncology company established in 2002 and headquartered in Taiwan. Together with its subsidiary OBI Pharma USA, Inc., the company is dedicated to developing innovative cancer therapeutics to provide new treatment options for patients with urgent medical needs.OBI's research efforts center on novel antibody-drug conjugates (ADC). Through its patented next-generation conjugation technology platform, Obrion™, OBI has established diverse ADC design modalities. The platform integrates proprietary conjugation and linker technologies, including GlycOBI®, GlycOBI DUO®, EndoSymeOBI®, HYPrOBI®, and the novel irreversible cysteine-conjugation technology ThiOBI® , to advance next-generation ADC solutions. OBI has developed a next-generation suite of ADC programs. These include monospecific ADCs such as OBI-902 (TROP2), which is under Ph1 clinical evaluation, and OBI-904 (Nectin-4); a bispecific single-payload ADC, OBI-201 (HER2 x TROP2); and a bispecific dual-payload ADC, OBI-221 (cMET x HER3). To broaden the applicability of the HYPrOBI® linker technology, OBI has further developed the ThiOBI® technology to enable irreversible cysteine-based conjugation. In addition to its ADC programs, OBI's assets include OBI-3424, a first-in-class AKR1C3-targeted small-molecule prodrug that selectively releases a potent DNA-alkylating agent in the presence of the aldo-keto reductase 1C3 enzyme, which is highly expressed in certain tumors. Additional information can be found at www.obipharma.com.About OBI-902 and OBI-992OBI-902 is a TROP2-targeted antibody-drug conjugate (ADC) that carries a potent topoisomerase I inhibitor payload to kill tumor cells with a drug-antibody ratio (DAR) of 4. TROP2 is highly expressed in a variety of solid tumors such as breast, lung, biliary, bile duct (cholangiocarcinoma), ovarian, gastric, and many other cancer types, rendering it an ideal target for cancer therapy.OBI-902 is a novel site-specific glycan-conjugated ADC using OBI's proprietary GlycOBI® platform, which provides improved stability and enhanced hydrophilicity. OBI-902 demonstrated remarkable antitumor efficacy across multiple tumors, including NSCLC, triple-negative breast cancer (TNBC), and gastric cancer, improved pharmacokinetic characteristics, and a favorable safety profile in various animal models. The IND of OBI-902 was cleared by the United States Food and Drug Administration (US FDA) on April 30, 2025, received Orphan Drug Designation (ODD) from the US FDA for cholangiocarcinoma on Nov. 16, 2025, and gastric cancer (GC), including gastroesophageal junction cancer (GEJC) on December 5, 2025.The Phase 1/2 Study (NCT07124117) is ongoing, with completion of the Phase 1a portion targeted for 1H 2027.OBI-992 is a TROP2-targeted antibody-drug conjugate (ADC) that carries a potent topoisomerase I inhibitor payload with drug-to-antibody ratio of 4 (DAR 4) via a cysteine conjugated, hydrophilic and enzyme-cleavable linker. OBI-992 remains stable in circulation and delivers this cytotoxic payload to TROP2-expressing tumor cells, leading to tumor cell death while avoiding off-target toxicities.The US FDA cleared the IND application for OBI-992 in Jan 2024 and subsequently granted Orphan Drug Designation for the treatment of gastric cancer, including GEJC in Aug 2024. The Phase 1/2 Study (NCT06480240) has reached the putative Recommended Phase 2 Dose (pRP2D) and Phase I completion is targeted for 1H 2027.Since December 2021, OBI has been granted by Biosion, Inc. (www.biosion.com) an exclusive license to a TROP2 targeting antibody amino acid sequence in all jurisdictions except Mainland China, Hong Kong and Macau. Biosion holds exclusive rights to that antibody sequence in Mainland China, Hong Kong and Macau. OBI holds commercial rights to OBI-992 and OBI-902 in all jurisdictions except Mainland China, Hong Kong and Macau, while Biosion holds commercial rights to OBI-992 and OBI-902 in Mainland China, Hong Kong and Macau.About OBI-904OBI-904 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody specifically targeting Nectin-4 (Nectin cell adhesion molecule 4), linked to a potent topoisomerase I inhibitor payload with Drug-to-Antibody Ratio of 8 (DAR8) through OBI's proprietary GlycOBI® ADC enabling technologies, powered by a dual-function enzyme, EndoSymeOBI®, and a novel linker, HYPrOBI®. It is a potentially first-in-class and best-in-class glycan-based ADC designed to target multiple cancer types that express Nectin-4. Antitumor activity has been shown across several animal disease models, including HNSCC, CRC, TNBC, cervical and sarcoma cancers; OBI-904 has demonstrated a favorable safety profile in a repeat dose toxicity study in monkeys, and is now in the pre-IND stage of development.About OBI-201OBI-201 is a TROP2 x HER2 bispecific ADC generated by OBI GlycOBI® ADC enabling technologies conjugated with a topoisomerase I inhibitor. Notably, OBI is the first to demonstrate that HER2 and TROP2 can interact and form a protein complex on the cell surface-a groundbreaking discovery facilitated through collaboration with a specialized AI drug discovery partner. OBI-201 offers several advantages over mono-specific TROP2 or HER2 ADCs. By targeting both antigens, it broadens tumor coverage, especially in cancers with heterogeneous or low expression of either target. Dual targeting can enhance tumor selectivity, binding avidity, and internalization, improving payload delivery to cancer cells while potentially reducing toxicity to normal cells. OBI-201 may overcome resistance associated with downregulation of targets after treatment by certain monospecific ADCs.Animal studies revealed that OBI-201 demonstrated significantly superior anti-tumor activity compared to single-target ADCs in drug-resistant breast cancer models with extremely low HER2 expression. OBI-201 was able to sustain tumor growth suppression, indicating its potential to overcome multiple drug-resistance mechanisms. OBI-201 is a next-generation bispecific ADC poised to break through the limitations of single-target ADCs, potentially offering patients a more comprehensive and durable treatment option.About OBI-221OBI-221 is a Bispecific-Dual Payload ADC (BsDpADC), generated by OBI GlycOBI DUO® technologies, targeting cMET and HER3, conjugated with dual payload of MMAE and topoisomerase I inhibitor.In clinical practice, EGFR-targeted therapies have become a key strategy for treating non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) patients. However, tumors often rapidly develop resistance by upregulating cMET and HER3 that, in turn, sustain tumor growth. Moreover, high expressions of cMET and HER3 have been observed in gastric cancer, head and neck cancer, and various other solid tumors, further underscoring the unmet medical needs.To address this challenge, OBI Pharma leverages its proprietary GlycOBI DUO® platform and HYPrOBI® linker to develop a novel bispecific dual-payload antibody-drug conjugate (BsDpADC)-OBI-221. This therapeutic agent simultaneously targets cMET and HER3 while delivering synergistic cytotoxic agents, effectively combating tumor resistance and heterogeneity. This breakthrough design not only addresses an unmet medical need but also represents a forward-looking strategy for next-generation ADC development.OBI-221 holds meaningful potential to overcome resistance to existing EGFR-targeted therapies, potentially offering patients more targeted treatment options while delivering substantial clinical value.About GlycOBI®OBI has developed a unique glycan-based, site-specific ADC technology (GlycOBI®), designed in a Plug and Play format that is compatible with any antibodies, linkers, and payloads, and supports various drug-antibody ratios (DAR)(up to 16). Powered by OBI's proprietary dual-function enzymatic technology EndoSymeOBI® and its hydrophilic linker technology HYPrOBI®, GlycOBI®, a core component of OBI's Obrion™ ADC technology family, enables the generation of site-specific and homogeneous ADCs through an efficient, scalable and streamlined two-step, one-pot conjugation process under GMP conditions.During the conjugation process, GlycOBI® avoids disrupting the antibody structure and ensures that the resulting ADC retains biophysical characteristics comparable to the native antibody. In addition, OBI's linker technology improves payload conjugation efficiency and reduces the propensity for aggregation or degradation, further supporting a stable and well-controlled ADC manufacturing process. GlycOBI® has overcome limitations commonly associated with traditional ADC approaches and has demonstrated improved antitumor activity and stability in various in vivo studies. Notably, the platform supports the conjugation of both cytotoxic small-molecule inhibitors and highly hydrophobic degraders, expanding its applicability to next-generation modalities such as DACs.About GlycOBI DUO®GlycOBI DUO® is a next-generation dual-payload antibody-drug conjugate (ADC) technology built on the GlycOBI® site-specific conjugation platform and its proprietary enzymatic conjugation strategy. It enables the precise and programmable attachment of two distinct payloads to a single antibody with tunable ratios and supports high DAR ratios, including up to DAR24. By combining complementary mechanisms of action, GlycOBI DUO® is designed to enhance antitumor efficacy, address tumor heterogeneity, and improve the overall therapeutic index, with the potential to overcome resistance mechanisms associated with conventional ADCs-representing a promising advancement in next-generation ADC development.About ThiOBI®OBI has developed a novel irreversible, cysteine conjugation ADC platform (ThiOBI®) with improved stability, which can apply to any antibodies, linkers, and payloads. OBI's proprietary ThiOBI® platform including linker technologies (HYPrOBI®) can generate ADCs in different biomolecular formats, including antibody fragments, nanobodies, peptides, and proteins. Furthermore, OBI's HYPrOBI® linker technology has improved conjugation efficiency of the payload and reduced aggregation propensity and also expanded the half-life of the ADC products. ThiOBI has overcome the limitations of traditional cysteine ADCs and achieved better antitumor activity and stability in various in vivo tests.GlycOBI®, EndoSymeOBI®, ThiOBI®, HYPrOBI®, and GlycOBI DUO® are registered trademarks of OBI. Obrion™ is a trademark under registration.Forward-Looking StatementsStatements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.COMPANY CONTACT:Jukka MuhonenExecutive Director, Business DevelopmentOBI Pharma USA, Inc.1.617.821.0292jukkamuhonen@obipharma.comSOURCE: OBI Pharma USA, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月15日 - (亚太商讯 via SeaPRwire.com) - 品创控股有限公司（"品创控股"或"公司"，连同其附属公司统称为"集团"；股份代号：8066）欣然宣布，集团全资附属公司赛博幻境（香港）有限公司（"赛博幻境"）于今日隆重举行《语音 AI 之 Echo 生态战略全球启幕盛典》，正式启动其全球语音 AI 回声生态系统（Echo Ecosystem，"回声生态"）战略，构建从语音数据采集、处理到商业应用的全链路闭环。此举标志着集团在人工智能语音数据服务领域的战略布局迈入全新阶段，为集团深化 AI 业务转型、打造长效增长曲线奠定坚实基础。针对语音数据采集规模、质量与多样性的行业困境，赛博幻境创造性推出区块链游戏与语音数据采集相结合的全新模式。用户参与游戏时，完成指定文本的语音录制任务，既可享受游戏乐趣，亦可获得代币激励。该"游戏化采集"模式，可大规模、高效率获取覆盖不同年龄、地域、口音与情感表达的真人语音数据，为构建多元化声音数据库提供稳定持续的来源。采集完成后，回声平台透过专业清洗、标注与分类处理，将原始语音转化为可直接用于 AI 训练的结构化声音数据库。相关数据库于 AI 数据市场以回声代币交易，供全球开发者及企业采购使用，形成"用户参与采集 — 获取代币激励 — 数据加工处理 — 市场交易流通 — 产业应用赋能"的完整价值链闭环。该模式不仅大幅降低语音 AI 开发门槛，更让数据贡献者、开发者及终端用户共享语音 AI 发展所带来的裨益。"语音 AI 不仅是技术，更是未来数字世界的入口。"赛博幻境首席执行官郭晓鹏先生在盛典上表示，"回声生态致力于构建语音 AI 时代的基础设施，透过去中心化的数据采集网络和开放的声音数据库市场，我们将为全球 AI 开发者提供最丰富、最优质的声音数据资源，推动语音 AI 技术在各行各业的快速落地和应用创新。"当前，人工智能技术加速渗透各行各业，人机对话已成为 AI 应用场景的核心交互方式。语音 AI 技术作为 AI 智能体不可或缺的组成部分，正成为连接人类与数字世界的入口。高品质、多元化的声音数据库是 AI 智能体强化训练的核心基础，语音 AI 技术发展已进入"数据驱动"新阶段，优质声音数据库不仅可显著提升语音合成的情感表现力、语音识别的场景适应性与对话系统的个性化能力，更成为语音 AI 产业发展的核心竞争力与先发优势所在。品创控股锐意推动业务多元化布局，把握数字经济与人工智能产业的蓬勃商机，并凭借前瞻性转型，成功构建"私域电商营运+AI技术服务"双轮驱动的业务架构。本次回声生态全球启动，是集团深化AI业务布局、推动主营业务向AI数据服务转型的关键里程碑。展望未来，集团将以赛博幻境为核心载体，持续深耕语音AI技术研发，拓展生态合作网络，推动技术在智能客服、数字人、元宇宙、智能汽车等前沿领域深度融合；同时深化两大业务协同效应，强化核心竞争力，推动业务高质量发展，把握全球AI产业广阔机遇，致力为股东创造可持续长期回报。图片说明赛博幻境首席执行官郭晓鹏先生讲解去中心化语音网络的价值实现，彰显品创控股推动语音 AI 技术在各行各业的快速落地和应用创新的决心。关于品创控股有限公司品创控股有限公司的使命是妥善运用公司所获得的资本与独特投资机会，为股东提供稳定的优渥收入与获利。品创控股由六个主要事业部门组成，包括智能卡制造服务、电子商务、人工智能、投资服务、资源回收投资与媒体与娱乐投资，主要业务为生产及销售智能卡、提供定制智能卡应用系统、私域电子商务平台营运、人工智能语音技术数据服务、提供财务及管理咨询服务、废旧金属销售及贸易、以及媒体与娱乐行业之投资。公司的总部位于香港，旗下控股公司与投资则遍布大中华地区。关于赛博幻境（香港）有限公司赛博幻境（香港）有限公司是品创控股有限公司的全资子公司，专注于语音人工智能技术的研发与应用。赛博幻境致力于通过创新的生态模式，打造从数据采集、处理到商业落地的全链条语音AI解决方案，助力全球智能语音产业的发展。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月15日 - (亚太商讯 via SeaPRwire.com) - 中国领先循环经济产业新消费公司转转集团（下称：转转）近日宣布，其自主研发的AI鉴定产品「AI拍图验真」已在二手奢侈品鉴定领域取得重大突破，鉴定准确率实现了LV包袋鉴定错误率不足万分之一、GUCCI包袋零错误的卓越表现；鉴定效率提升近900倍至「1秒出结果」。集团今年将逐步把AI鉴定拓展至CHANEL、Hermès等热门品牌，并于未来延伸至腕表等其他二手品类，构建全品类AI鉴定矩阵。凭借其顶尖AI鉴定能力及创新业务模式的领先优势，转转同步计划在香港设立国际业务总部，正式开启全球化布局。作为中国头部二手交易平台，转转自2015年成立以来发展迅速，旗下拥有转转、找靓机、红布林等多个知名二手消费品牌。当前中国二手闲置赛道备受资本与市场瞩目，转转亦凭借首创的二手质检「官方验」服务脱颖而出。集团已获包括腾讯、小米、58集团在内的多个知名企业或投资者支持，上一轮融资估值达逾30亿美元（约234亿港元），去年营收总额突破200亿元人民币，拥有超过4亿注册用户、5,000万月活跃用户。 （图为北京「超级转转」二奢仓店）有别于以Carousell、闲鱼等企业为代表的传统C2C模式，转转透过成熟的C2B2C商业模式，以「平台居中、专业鉴定、品质保证」提供差异化平台服务。其首创的「官方验」服务会在对回收商品全方位严格检测后为其提供一份专属的质检报告并公开展示，绝大部分官方验商品，都可享有7天无理由退货、一年平台质保、内陆包邮等增值服务。转转透过标准化质检与售后保障，例如履行「验了再发货」、「不满意可退」、「验错了就赔」等策略，为消费者提供「所见即所得」的优质体验。 （图为转转青岛智能质检中心）技术驱动是转转稳居行业领先地位的核心引擎。转转去年成立了AI事业部，三年内拟投入20亿元人民币研发AI质检、智能匹配等工具。今年初上线的「AI拍图验真」，深度应用于二手奢侈品鉴定领域，系统基于海量真实商品图片数据库与深度学习算法，将传统需时15分钟的人工鉴定大幅压缩至「秒级鉴定」，最快1秒即可出结果，效率提升近900倍;同时在核心包袋品类的鉴定上，更创下错误率不足万分之一的超高准确率（上线至今，LV包袋累计鉴定逾万单，仅错一单，错误率不足万分之一），彻底打破了传统非标品交易及人工鉴定中的标准不一、效率樽颈等难题。转转集团创办人兼行政总裁黄炜表示：「转转集团在过去十年间通过持续的技术创新和战略整合，确立了在中国二手交易市场的领导地位，我们深信领先的技术与质检能力是打破二手交易壁垒的关键。转转致力引领中国的二手消费模式，不断刷新消费者的二手消费体验，我们对即将在香港设立国际业务总部感到振奋，亦是标志着转转从中国市场迈向国际舞台的重要里程碑。」 （图为转转APP内商品AI鉴定信息）关于转转转转集团成立于2015年，是中国领先的循环经济产业新消费公司，旗下拥有转转、找靓机、采货侠、侠客汇、红布林等多个二手电商品牌，业务覆盖手机3C、奢侈品、图书、潮玩等百余种余种品类二手商品交易，在全国布局超过1,100多家线下门店和超过3,000人的上门回收团队，通过人工智能质检技术和创新的C2B2C商业模式，致力解决非标品交易的信任难题，为消费者带来有质价比的二手好物。转转作为全国有履约二手商品交易平台的领导企业，去年已录得超过4亿注册用户、5000万月活跃用户。「技术驱动+平台服务」为核心引擎，转转特设AI事业部，在国立首创二手质检「官方验」服务，并先后自主研发AI估价系统、AI拍图验真等核心技术产品，打造了二奢行业的顶尖AI鉴定能力，为全球知名热门的奢侈品牌包袋品类提供秒级且精准的真伪鉴定，持续引领中国二手交易市场向标准化、数字化迈进。传媒垂询，请联络：转转集团公关部 Alan Wei：weixi@zhuanzhuan.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Apr 15, 2026 - (ACN Newswire via SeaPRwire.com) - As artificial intelligence adoption accelerates across Southeast Asia, enterprises across the ASEAN region are increasingly establishing structured AI engineering practices to move from experimentation to production-scale deployment.According to Joseph Bosco, Partner Manager, APJ - Prof Services at Databricks, organisations across ASEAN are recognising that sustainable AI adoption depends not only on advanced models but also on robust engineering foundations that ensure reliability, governance and operational scalability.“The early phase of AI adoption focused heavily on experimentation and proofs of concept,” Bosco said. “Across Southeast Asia we are now seeing a shift towards AI engineering practices that prioritise data quality, governance and production readiness.”Markets such as Singapore, Indonesia, Vietnam, Malaysia and Thailand are witnessing strong momentum in enterprise AI adoption as organisations modernise their data infrastructure and invest in advanced analytics capabilities.Industry experts note that AI engineering is becoming a critical discipline that connects AI innovation with enterprise operations. This includes building scalable data pipelines, managing machine learning lifecycle processes and integrating AI systems into business workflows.“Building a model is only one part of the challenge,” Bosco said. “The real work lies in creating reliable data pipelines, managing model lifecycle and embedding AI into operational systems.”Across ASEAN, many enterprises continue to manage complex data environments spanning legacy systems, multiple cloud platforms and software-as-a-service applications. Consolidating these fragmented data sources into unified platforms is increasingly seen as a prerequisite for scaling AI initiatives.Technology partners and consulting firms across the region are responding by developing dedicated AI engineering practices that combine expertise in data engineering, machine learning, generative AI and governance frameworks.These capabilities are already being applied across key sectors including financial services, telecommunications, and manufacturing.Bosco noted that Southeast Asia’s rapidly expanding data economies are creating a particularly dynamic environment for AI engineering talent and innovation.“As organisations across ASEAN continue to invest in data transformation, AI engineering will become an essential capability that enables enterprises to operationalise AI safely and effectively,” he said. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

KUALA LUMPUR, Malaysia, April 14, 2026 - (ACN Newswire via SeaPRwire.com) - Exito Media Concepts today announced the 46th Edition of the Digital Transformation Summit Malaysia 2026, convening on 23rd April 2026 at the Hyatt Regency Kuala Lumpur Midtown. The summit will bring together more than 200 C-Level executives, technology directors, and government leaders to address the strategic and operational imperatives shaping Malaysia's next phase of digital growth.Now in its 46th edition and part of a series spanning 11+ countries, the summit has established itself as one of Asia Pacific's most consequential forums for enterprise technology leadership.The Strategic Context: Malaysia's Digital Economy at a Critical JunctureMalaysia's digital economy is undergoing a structural shift. Driven by targeted government-led initiatives and accelerating enterprise adoption of artificial intelligence, the Internet of Things, and Web 3.0, organizations across every sector are fundamentally reimagining how they operate, compete, and deliver value.The opportunity is significant. Yet the path to enterprise-wide transformation demands more than technology investment — it requires navigating complex cybersecurity environments, integrating legacy infrastructure with modern digital architecture, developing organizational capabilities at pace, and embedding a culture of innovation that sustains long-term resilience. For Malaysia's business leadership, strategic clarity has never been more consequential.The Digital Transformation Summit Malaysia 2026 is designed precisely for this inflection point.Enterprise Transformation in PracticeThe business case for bold digital action is already being written across Malaysia. A leading domestic enterprise recently undertook a comprehensive digital transformation initiative — transitioning to a cloud-first infrastructure supported by advanced data analytics and AI capabilities.The results were measurable and material: automating key operational processes delivered significant gains in efficiency and organizational agility. The concurrent deployment of robust cybersecurity frameworks ensured data integrity and regulatory compliance. Simultaneously, structured workforce upskilling programmes enabled teams to perform with confidence in an evolving technology environment.The outcome: improved business performance, deeper customer engagement, and a materially stronger competitive position within Malaysia's digital economy. It is precisely this calibre of real-world insight that the Summit is built to surface and scale.Event OverviewThe 46th Edition of the Digital Transformation Summit Malaysia 2026 is part of a globally recognized series of events hosted across 11+ countries. This edition will convene more than 200 C-Level Executives, Directors, Heads of Technology, Government leaders, and digital transformation leaders from across industries.Through expert-led keynotes, panel discussions, and real-world case studies, the summit will highlight innovative strategies, emerging technologies, and actionable insights that empower organizations to drive digital growth and operational excellence.Date: 23rd April 2026Time: 09:00 AM to 05:00 PMVenue: Hyatt Regency Kuala Lumpur MidtownWebsite: https://digitransformationsummit.com/malaysia/Summit Agenda: Technology Priorities Shaping 2026Delivered through expert-led keynotes, high-impact panel discussions, and documented case studies, the Summit agenda will address the technology priorities most consequential to enterprise leaders this year:Artificial Intelligence & Machine Learning Embedding intelligent decision-making and automation across core business functions — from supply chain to customer experience to financial operations.Web 3.0 & Emerging Technologies Navigating decentralized innovation and unlocking new digital ecosystems with long-term enterprise relevance.Internet of Things (IoT) Advancing operational connectivity and efficiency across industries through integrated sensor and data infrastructure.Quantum Computing Examining the practical and strategic implications of the next frontier in computational capability.Cybersecurity & Data Protection Strengthening enterprise digital resilience against an increasingly sophisticated and expansive threat landscape.Cloud & Scalable Infrastructure Building the foundational agility, continuity, and scalability demanded by modern enterprise growth.Digital Culture & Transformation Strategy Developing the leadership frameworks and organizational behaviours that sustain transformation well beyond initial implementation.Data-Driven Decision Making Harnessing analytics to convert raw data into competitive intelligence and measurable business outcomes.About Exito Media ConceptsExito — the word for success — is both the name and the operating philosophy of one of the world's most active B2B events and media organizations. Over 16 years, Exito has built a reputation for delivering 240+ conferences annually across technology, digital transformation, cybersecurity, healthcare, and emerging enterprise sectors worldwide.Every Exito event is defined by meticulous agenda curation, access to world-class speaker communities, and a commitment to market-driven insight that translates directly into strategic value for attendees, sponsors, and partners. The result is a global platform trusted by thousands of senior executives to inform their most consequential decisions.Media ContactPrakruthi NayakaMedia and PR Executive, Exito Media ConceptsEmail: prakruthi.nayaka@exito-e.comWebsite: https://digitransformationsummit.com/malaysia/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月15日 - (亚太商讯 via SeaPRwire.com) - 4月13-14日，2026年世界互联网大会亚太峰会在香港会议展览中心举办。百望股份首席战略官刘扬发表了题为《全球税务合规：从"财税数字化"到"中国企业商业信用基础设施"》的主题演讲，深度分享百望股份全球化战略布局与落地进程，全面展示了百望以AI Agent重构跨境税务合规体系、搭建中国企业商业信用基础设施的创新实践。 本次峰会以"数智赋能 创新发展——携手构建网络空间命运共同体"为主题，由世界互联网大会主办，香港特别行政区政府承办，香港特别行政区政府创新科技及工业局等协办。香港特别行政区行政长官李家超出席开幕式并致辞。来自全球50余个国家和地区的政府部门部长级官员、国际组织高级别代表、驻华使节、互联网领军企业代表，以及专家学者等约千名嘉宾参会。百望以商业信用模型架构为核心，筑造AI能力壁垒本次世界互联网大会的亮相，是百望股份上市以来完成AI战略转型后，首次在世界级行业论坛的重磅发声，也是企业全球化战略的一次全面公开发布。会上，百望股份宣告已完成全球化智能科技公司的全面能力准备，以商业信用模型为核心架构，正式开启全球化发展新篇章。百望股份是本次大会中唯一一家实现垂直大模型企业级应用落地、且拥有规模化真实商业案例的企业，充分印证了在AI企业级应用赛道的领先身位，全面彰显了百望股份核心战略的前瞻性与正确性，验证了以数据智能为核心、以AI Agent为抓手、以全球化布局为增长曲线的长期战略布局的精准判断。基于对AI Agent 时代企业级需求的深度理解，百望股份以动态商业信用模型为核心，完成了产品架构的全面升级，打造了"底层底座-能力中枢-智能执行"的完整闭环产品体系。百望股份之能成为中国企业商业信用基础设施的构建者，核心根基就藏在这一架构的底层设计逻辑之中。整个架构以算力平台为底层支撑，向上搭建了数据中台、AI中台、能力中台三位一体的技术中台体系。基于交易关系、商品关系、制度关系、金融关系、雇佣关系五大维度，百望股份形成了以百望企信码为底层底座，以百链、百信、百策为数据核心能力中枢，以百望百宝、百望百搭为智能执行应用的群体智能矩阵。区别于传统财税软件的功能叠加模式，百望股份打造的是可生长、可扩展的智能技术底座，这也是商业信用基础设施能够持续迭代、适配全球多元场景的核心前提。作为一家善用数据的科技公司，百望股份始终将真实交易数据作为AI时代的核心竞争力，过去十年累计处理发票超 260 亿张，沉淀了覆盖 9600万余个市场主体的海量高质量真实交易底账数据，成为企业AI 能力建设的核心燃料！百望Tax-Swift护航中企全球化征程，全面印证场景落地能力作为百望股份全球化战略的核心场景落地产品，Tax-Swift全球虚拟税务平台基于沉淀10年的监管科技与规则引擎能力，完成了全球化适配与升级，为中国企业的全球化征程搭建起全链路的合规屏障。具体而言，Tax-Swift以AI技术为核心驱动力，构建了覆盖全球税务合规全流程的闭环服务体系。平台依托全球引擎基座、发票引擎、税务规则引擎、国家适配器四层核心架构，可自动完成多语言转换、实时汇率校准、多格式报文转换、电子签名校验、智能算税算法、合规风险过滤、税收优惠适配等全流程操作，实现了企业ERP系统到全球各国税务系统的无缝直连，可深度适配全球主流税务监管体系。目前，平台已覆盖10余种主流语言、200余种票据格式标准、3万余条国际财税规则，已在多个中企出海场景落地见效。例如，某中国餐饮集团出海越南时，接入Tax-Swift平台后，顺利完成了越南当地门店的税务合规体系搭建，实现了规模化落地。今年初，百望再度升级推出Tax-Swift Bai-Claw（全球税务数字员工平台），可覆盖全球50余个国家和地区的财税合规需求，AI数字员工全面掌握权威财税政策、行业知识与专业技能，可根据企业需求定制化部署，成为中企出海随身随行的合规哨兵。百望股份CSO刘扬在演讲中表示："政策、数据、AI与全球化正在形成新的共振。交易无国界，纳税有主权，全球数字贸易正在进入主权卡位与信用卡位的全新阶段。百望股份期望以本次峰会为契机，持续深化技术创新与产业实践，以数智能力筑牢中国企业出海的合规屏障，以商业信用基础设施赋能全球贸易的高质量发展，携手各界伙伴共同赋能国家一带一路战略，为构建网络空间命运共同体贡献力量。"随着AI技术的持续深化与全球化布局的稳步推进，百望股份正在以技术创新打破跨境贸易的合规壁垒，为中国企业出海铺就一条安全、高效的数字化通路，在全球数字贸易的新赛道上，书写中国科技企业的全新篇章。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com